All In Biotech

Drug Trial Radar · NCT07254871

Study of DM-101PX in Adults With Birch Pollen Allergy

A Phase 2, Randomized, Double-Blind, Placebo-controlled Study to Investigate the Safety and Efficacy in Reducing Nasal Allergen Challenge Provoked Symptoms of Treatment With DM-101PX in Adults With Birch Pollen Allergic Rhinitis or Rhinoconjunctivitis

Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

97

Actual

Start

Sep 26, 2025

Primary completion

Apr 15, 2026

Study completion Aug 10, 2026

Sponsor

Lead sponsor
Desentum OyIndustry
Sponsor type
Industry
First posted
Nov 28, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Randomized, double-blind placebo-controlled phase 2 trial with the aim to investigate safety and efficacy of DM-101-PX in reducing allergic symptoms provoked by nasal allergen challenge in birch pollen allergic adults. Expanded access to the study treatment is not available.

Conditions

  • Birch Pollen Allergy

Interventions

  • DM-101PXBiological

    subcutaneous injection of DM-101PX

  • PlaceboBiological

    Placebo to match DM-101PX administered subcutaneously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Total Nasal Symptom Score (TNSS) after treatmentTime frame: From baseline to 3 weeks after the last dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cliantha Research

    Mississauga, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.